(2R,5S)-Ritlecitinib

• UNSPSC Description:

  (2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/2r-5s-ritlecitinib.html

• Purity:

  99.77

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  C[C@@H]1CC[C@@H](CN1C(C=C)=O)NC2=C3C=CNC3=NC=N2

• Molecular Weight:

  285.351

• References & Citations:

  [1]Atli Thorarensen, et al. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides. US20150158864A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  1792180-79-0